title: [Long-term results of neoadjuvant radiochemotherapy in squamous carcinoma of the thoracic esophagus].
abstract: OBJECTIVE
  Surgery is considered the mainstay of therapy for clinically resectable esophageal cancer, even though neoadjuvant treatments are frequently added. The aim of this study was to analyse our experience on neoadjuvant treatment of squamous cell carcinoma of the thoracic esophagus with special reference to long-term
  
  
  RESULTS
  
  
  
  METHODS
  The results of 66 patients who underwent neoadjuvant chemo-radiotherapy for squamous cell carcinoma of the thoracic esophagus at the 1(st) Division of General Surgery, University of Verona, from February 1995 to December 2002 were analysed statistically. The median follow-up period for the surviving patients was 65.3 months.
  
  
  RESULTS
  The induction treatment was completed in 93.9% of cases, with a null treatment related mortality and a complication rate of 34.8%. Sixty-one out of the 66 patients (92.4%) underwent resection with a R0-resection rate of 83.9%. A major pathological response (responders) was gained in 42.6% of the cases, with a complete response (pTONO) observed in 29.5% of the cases. Overall 5-year survival for the 66 patients was 30%, while the 5-year survival rate raised to 43% in R0-patients. A better long-term survival was observed for responders with respect to ''non-responders'' with a 5-year survival rate of 70% and 13%, respectively (P<0.001).
  
  
  CONCLUSIONS
  This neoadjuvant protocol regimen represents a feasible treatment with an acceptable morbidity. The tumor efficacy in term of pathological responses was similar to literature
  
  
  RESULTS
  An high rate of R0-resections was achieved with a possibility of cure limited to this group of patients. A better long-term survival was observed in patients with major pathological responses.
authors.affiliation: Prima Divisione Clinicizzata di Chirurgia Generale, Università di Verona, Piazzale Stefani 1, 37126 Verona, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Pedrazzani
authors.forename: E
authors.initials: E
authors.lastname: Laterza
authors.forename: F
authors.initials: F
authors.lastname: Pasini
authors.forename: A
authors.initials: A
authors.lastname: Grandinetti
authors.forename: M
authors.initials: M
authors.lastname: Bernini
authors.forename: S
authors.initials: S
authors.lastname: Giacopuzzi
authors.forename: G
authors.initials: G
authors.lastname: Zerman
authors.forename: S
authors.initials: S
authors.lastname: Tasselli
authors.forename: A
authors.initials: A
authors.lastname: Ruzzenente
authors.forename: G
authors.initials: G
authors.lastname: De Manzoni
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D015996:Survival Rate; D013997:Time Factors
chemical_list: D002945:Cisplatin; D005472:Fluorouracil